Pneumothorax Treatment Devices Market Report 2026

Pneumothorax Treatment Devices Market Overview

• Pneumothorax Treatment Devices market size has reached to $3.98 billion in 2025 • Expected to grow to $6.43 billion in 2030 at a compound annual growth rate (CAGR) of 10% • Growth Driver: Rising Respiratory Diseases Fuel Growth In The Market • Market Trend: Advancements In AI-Enabled Chest X-Ray Solutions For Pneumothorax Detection • North America was the largest region in 2025.

What Is Covered Under Pneumothorax Treatment Devices Market?

Pneumothorax treatment devices are medical instruments used to manage and treat the condition of a collapsed lung, where air accumulates in the pleural space. Their purpose is to remove the excess air, restore lung expansion, and prevent further complications, often through techniques such as needle decompression or chest tube insertion. The main types of pneumothorax treatment devices are ventilator devices, thoracic vent devices, and other types. Ventilator devices in pneumothorax treatment are used to assist or control breathing by delivering air to the lungs, helping to maintain oxygen levels and prevent further lung collapse during recovery. It is utilized for various applications, including traumatic pneumothorax, spontaneous pneumothorax, and others, across settings such as hospitals, ambulatory surgical centers, and additional end users.

What Is The Pneumothorax Treatment Devices Market Growth Forecast?

The pneumothorax treatment devices market size is expected to see rapid growth in the next few years. It will grow to $6.43 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to growth in portable emergency devices, advancements in thoracic vent systems, increased ICU admissions, demand for faster lung re-expansion, emergency medical service expansion. Major trends in the forecast period include rapid emergency lung decompression, portable pneumothorax management devices, minimally invasive chest drainage, improved air leak control systems, simplified bedside treatment kits.

Global Pneumothorax Treatment Devices Market Segmentation

1) By Type: Ventilator Devices, Thoracic Vent Devices, Other Types 2) By Application: Traumatic Pneumothorax, Spontaneous Pneumothorax, Other Applications 3) By End-User: Hospitals, Ambulatory Surgical Centers, Other End Users Subsegments: 1) By Ventilator Devices: Portable Ventilators, Non-Invasive Ventilators, Invasive Ventilators 2) By Thoracic Vent Devices: Chest Drainage Systems, Heimlich Valves, One-Way Chest Valve Systems 3) By Other Types: Needle Aspiration Devices, Pleural Catheters, Oxygen Therapy Devices

What Is The Driver Of The Pneumothorax Treatment Devices Market?

The increasing number of respiratory diseases is expected to propel the growth of the pneumothorax treatment devices market. Respiratory diseases are medical conditions that affect the lungs and airways, impairing breathing and oxygen exchange. Rises in respiratory diseases can be attributed to factors such as air pollution, smoking, viral infections, and increased exposure to allergens. Pneumothorax treatment devices are used in respiratory diseases to manage collapsed lungs and restore normal breathing function. For instance, in September 2025, according to the Australian Bureau of Statistics, an Australia-based government agency, deaths involving influenza increased from 611 deaths in 2023 to 806 deaths in 2024 and further to 1,057 deaths in the year to August 2025, representing a 73% increase from 2023 to the comparable August 2025 period. Deaths involving respiratory syncytial virus (RSV) rose from 380 deaths in 2023 to 468 deaths in 2024 and 399 deaths in the year to August 2025. Therefore, the increasing number of respiratory diseases drives the growth of the pneumothorax treatment devices industry.

Key Players In The Global Pneumothorax Treatment Devices Market

Major companies operating in the pneumothorax treatment devices market are Cardinal Health Inc., Medtronic PLC, Siemens Healthineers AG, Medline Industries Inc., Fujifilm Holdings Corporation, Becton Dickinson and Company (BD), GE HealthCare Technologies Inc., Stryker Corporation, Boston Scientific Corporation, Draegerwerk AG & Co. KGaA, Cook Medical Inc., B. Braun Melsungen AG, Utah Medical Products Inc., Rocket Medical plc, Nobelpharma Co. Ltd., Sinapi Biomedical Inc., UreSil Inc., ATMOS MedizinTechnik GmbH & Co. KG, Betaglue Technologies S.p.A., Selio Medical Inc.

Global Pneumothorax Treatment Devices Market Trends and Insights

Major companies operating in the pneumothorax treatment devices market are focusing on developing technologically advanced solutions, such as chest X-ray solutions, to sustain their position in the market. Chest X-ray solutions refer to imaging systems, equipment, and technologies designed to capture detailed radiographic images of the chest, including the lungs, heart, ribs, and surrounding structures. For instance, in September 2023, Qure.ai, a US-based health tech company, announced that it received 510(k) FDA clearance for its innovative chest X-ray solution, qXR-PTX-PE. This solution is designed to assist in the rapid detection of pneumothorax (PTX) and pleural effusion (PE). The AI-enabled software enhances care pathways in intensive care units (ICUs) and emergency rooms (ERs) by providing timely notifications to healthcare professionals. The qXR-PTX-PE solution analyzes chest X-ray images for critical findings, significantly improving triage efficiency in emergency settings, where these conditions pose serious risks to patient health.

What Are Latest Mergers And Acquisitions In The Pneumothorax Treatment Devices Market?

In June 2023, Merit Medical Systems, Inc., a US-based medical technology company focused on interventional, diagnostic, and critical care products, acquired AngioDynamics, Inc., for US$100 million in cash. With this acquisition, Merit Medical aims to strengthen and expand its interventional oncology and lung biopsy–related complication management portfolio by integrating the BioSentry system, which is specifically designed to reduce the incidence of biopsy-related pneumothorax, thereby enhancing its position in the global pneumothorax treatment devices market while also broadening its offering in vascular access and dialysis care. AngioDynamics, Inc., is a US-based medical device company specializing in minimally invasive vascular, oncology, and biopsy-related products.

Regional Outlook

North America was the largest region in the pneumothorax treatment devices market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Pneumothorax Treatment Devices Market?

The pneumothorax treatment devices market consists of sales of products including tubes, valves, suction devices and systems, and digital thoracic drainage systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.